P56 Preliminary study of anti-AAVrh74 seroprevalence following gene transfer

The increasing number of gene therapy studies and exclusion of candidates from clinical trials highlights the potential importance of pre-existing antibodies targeting viral capsid. Viral antibodies block transduction and preclude expression of the transferred gene. Provoked immune response could also be a threat to safety. Testing patients for pre-existing antibodies, either neutralizing (Nabs) or total/binding (TAbs/BAbs), prior to gene transfer is a critical step in the initiation of a clinical trial.
Source: Neuromuscular Disorders - Category: Neurology Authors: Tags: THERAPIES FOR NEUROMUSCULAR DISORDERS Source Type: research